CD4⁺ T Cells in Cancer

 Sunday, May 8, 2022     3:45 PM – 5:45 PM ET     Room A105–106

CD4⁺ T Cells in Cancer

Chairs

• Stephen Schoenberger, La Jolla Inst. for Immunology
• Steven Ziegler, Benaroya Res. Inst.

Speakers

• Spencer E. Brightman, La Jolla Inst. for Immunology, TCR-engineered neoantigen-specific CD4⁺ T cells mediate immunotherapy of a class II-negative murine squamous cell carcinoma
• Katelyn T. Byrne, Perelman Sch. of Med., Univ. of Pennsylvania, CD4⁺ T cells mediate non-canonical rejection of major histocompatibility class-I deficient pancreatic tumors independently of CD8⁺ T cells
• Dan Chen, Salk Inst. for Biological Studies, Dissecting anti-tumor immunity in glioblastoma
• Ying Zheng, Johns Hopkins Univ. Sch. of Med., Target the activin receptor 1c on CD4⁺ T cells to achieve anti-tumor therapeutic effects
• Hsin Yu Liu, La Jolla Inst. for Immunology, Leveraging the Treg-intrinsic CTLA4-PKCη signaling pathway for cancer immunotherapy
• Kazushige Obata-Ninomiya, Benaroya Res. Inst., Virginia Mason, Thymic stromal lymphopoietin (TSLP) receptor signaling controls a tumorigenic Treg to promote colorectal cancer
• Kai Yang, Indiana Univ. Sch. of Med., The glutathione peroxidase Gpx4 prevents Treg lipid peroxidation and ferroptosis to facilitate tumor immunoevasion